NEURALPLEXER
LIVE

Serial Number

99014025

Owner

Iambic Therapeutics, Inc.

Attorney

Alyssa M. Worsham

First Use Date

Sep 23, 2024

Filing Date

Jan 21, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NEURALPLEXER Trademark

Serial Number: 99014025

NEURALPLEXER is a trademark filed by Iambic Therapeutics, Inc. on January 21, 2025. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Iambic Therapeutics, Inc. (5 trademarks)

5627 Oberlin Drive, Suite 120
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

January 21, 2025

Registration Date

Not Registered

First Use Anywhere

September 23, 2024

First Use in Commerce

September 23, 2024

Published for Opposition

August 12, 2025

Goods & Services

Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction

Filing History

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 21, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 21, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jun 30, 2026 SUPC
USE AMENDMENT FILED
Apr 7, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 7, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 3, 2026 EXRA
SOU EXTENSION 1 GRANTED
Apr 2, 2026 EX1G
SOU EXTENSION 1 FILED
Apr 2, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 2, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 7, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 12, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 12, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 6, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 1, 2025 CNSA
ASSIGNED TO EXAMINER
Jul 1, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 25, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 21, 2025 MAFR
NEW APPLICATION ENTERED
Jan 21, 2025 NWAP